Cite
HARVARD Citation
Zhou, Y. et al. (2022). Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study. Therapeutic advances in gastroenterology. p. . [Online].